-- Poster presentation of MGTA-145 investigator-initiated Phase 2 clinical trial data confirmed previously reported positive topline clinical data for stem cell mobilization and transplant in multiple myeloma --
-- Phase 2 development of MGTA-145 to include new clinical trial designed to optimize the dosing and administration regimen of MGTA-145 plus plerixafor to streamline future clinical development and enhance the potential commercial profile --
-- Oral and poster presentations relating to preclinical transplant studies, including primate results, with tool CD117 antibody drug conjugates (ADC) further validate CD117-specific ADC-based conditioning for autologous stem cell gene therapy and allogeneic transplant --
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today highlighted three presentations made at the 2021 American Society of Hematology (ASH) Annual Meeting.
Stem Cell Mobilization: ASH Presentation and Clinical Development Plans
The data from an investigator-initiated Phase 2 clinical trial in multiple myeloma, presented on December 13, 2021, at the ASH Annual Meeting and previously reported in a Magenta press release on November 4, 2021, confirmed that MGTA-145 plus plerixafor (i) achieved the primary endpoint for collection of hematopoietic stem cells (HSCs), (ii) was well-tolerated and (iii) mobilized HSCs which were able to successfully engraft with positive 100-day outcomes. The data continue to support MGTA-145 plus plerixafor as a potentially compelling combination with complementary mechanisms of action.
Building upon the encouraging cell collection data from the Phase 2 investigator-initiated trial, Magenta plans to pursue a company-sponsored Phase 2 clinical trial in healthy subjects to further increase cell collection yield through adjustments of the dosing and administration regimen. This is a capital-efficient approach designed to enable expedited enrollment, flexibility in execution and reduced patient variability which will inform planned clinical trial evaluations in multiple myeloma patients and allogeneic stem cell transplant. Magenta will close its current allogeneic clinical trial while continuing to advance its MGTA-145 clinical trial in sickle cell disease in partnership with bluebird bio due to the predicted pharmacology of MGTA-145 and plerixafor in the sickle cell patient setting for HSC gene therapy.
We believe the current profile of MGTA-145 plus plerixafor, with enhanced cell collection yield, could provide significant clinical benefit to patients and favorably position the product commercially, said Jeff Humphrey, M.D., Chief Medical Officer, Magenta Therapeutics. We believe there are dosing and administration adjustments that could further improve cell collection and also expect that this proposed clinical trial will answer key clinical questions which could, ultimately, be major differentiators for the program moving forward.
Targeted Conditioning: ASH Presentations and Phase 1/2 Clinical Trial
Two presentations relating to Magentas MGTA-117 targeted conditioning program were made on December 11-12, 2021, at the ASH Annual Meeting. The first was an oral presentation of non-human primate data supporting the use of a CD117-targeted ADC to condition for HSC gene therapy. The second was a poster presentation of preclinical mouse data that supports the use of a CD117-targeted ADC in combination with lymphodepletion to condition prior to allogeneic HSC transplant. The results from these two presentations were previously disclosed in a press release by Magenta on November 4, 2021.
Gene Therapy. In support of using a CD117-targeted conditioning ADC in gene therapy, Dr. Naoya Uchida, staff scientist at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH), presented preclinical data generated using a tool CD117-targeted ADC in a clinically relevant and fully immune-competent primate gene therapy model for sickle cell disease. The data was generated as part of an NIH-funded (Grant No. HL006008), joint-research collaboration between Magenta and the NIH. The tool CD117-ADC uses the same antibody and engineering as MGTA-117, and although it utilizes a different payload, the results validate CD117 as a target for ADC-based conditioning because of (i) the value of the ADCs selectivity to the CD117-expressing hematopoietic stem cells and (ii) the effective cell depletion following delivery of an on-target, cell-killing payload. In primates, a single dose of CD117-ADC led to >99% depletion of stem cells, a reduction previously only achieved by four daily doses of busulfan chemotherapy. The data also showed successful engraftment of gene-modified cells with robust and durable fetal hemoglobin levels.
Magentas MGTA-117 clinical candidate uses an amanitin payload which has been shown preclinically to be a potent agent for stem cell depletion. Potent stem cell depletion is critical to making room in the bone marrow for engraftment of the modified cells used in gene therapy (and non-modified stem cells used in transplantation). Importantly, depleting CD117-expressing hematopoietic stem cells in a gene therapy setting may allow for the elimination of busulfan, other chemotherapies and irradiation and their known off-target and damaging adverse effects.
The results suggest that a single dose of a CD117-targeted ADC can enable comparable levels of gene-therapy cell engraftment to multi-dose busulfan while avoiding many of busulfans common toxicities, said Dr. John Tisdale, Chief of Cellular and Molecular Therapeutics, NHLBI, NIH. If successfully translated to the clinic, a single dose of a CD117-targeted ADC may improve the risk/benefit profile for patients with hemoglobinopathies who are considering HSC gene-therapy.
Allogeneic HSC Transplant. In support of using a CD117-targeted conditioning ADC in allogeneic HSC transplant, Magenta presented a poster demonstrating successful use of a tool CD117-ADC in combination with lymphodepleting antibodies that enabled allogeneic transplant in immune-competent murine models. These studies support the therapeutic potential of CD117-targeted ADCs, without the use of toxic chemotherapy, for conditioning in allogeneic HSC transplantation.
Phase 1/2 Clinical Trial. Magenta is on track to open a Phase 1/2 clinical trial this month to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MGTA-117, a CD117-targeted ADC. Preclinical efficacy and GLP toxicology studies with MGTA-117: (i) enabled selection of the starting dose in this dose-escalating Phase 1/2 clinical trial, (ii) demonstrated that MGTA-117 efficiently depleted stem cells, (iii) showed that MGTA-117 was efficiently cleared from the body in the preclinical models which is especially important for autologous gene therapy or allogeneic stem cell transplants, and (iv) showed that MGTA-117 was well-tolerated. MGTA-117, as a targeted conditioning therapy, is designed to substantially improve against the known safety and tolerability concerns of current non-specific conditioning agents which include busulfan, other chemotherapies, and irradiation. Magenta expects to provide the details of the MGTA-117 clinical trial design at its company presentation at the 2022 JP Morgan Healthcare Conference on January 13, 2022.
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
Magenta is based in Cambridge, Massachusetts. For more information, please visit http://www.magentatx.com.
Follow Magenta on Twitter: @magentatx.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magentas future expectations, plans and prospects, including, without limitation, statements regarding expectations and plans for the initiation and design of clinical trials, the development of product candidates and advancement of clinical programs, expectations for clinical trials results, the potential benefits and commercial profile of product candidates, as well as other statements containing the words anticipate, believe, continue, could, endeavor, estimate, expect, intend, may, might, plan, potential, predict, project, seek, should, target, will or would and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; whether interim results from a clinical trial will be predictive of the final results of the trial; the expected timing of submissions for regulatory approval or review by governmental authorities; discussions with governmental agencies such as the FDA; regulatory approvals to conduct trials or to market products; whether Magenta's cash resources will be sufficient to fund Magenta's foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, uncertainties and assumptions regarding the impact of the continuing COVID-19 pandemic on Magentas business, operations, strategy, goals and anticipated timelines, Magentas ongoing and planned preclinical activities, Magentas ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, Magentas timelines for regulatory submissions and Magentas financial position; and other risks concerning Magenta's programs and operations are described in additional detail in its Annual Report on Form 10-K filed on March 3, 2021, as updated by Magentas most recent Quarterly Report on Form 10-Q, and its other filings made with the Securities and Exchange Commission from time to time. Although Magenta's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005524/en/
Read more:
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
- Sight Care Reviews - Overpriced or Worth the Hype? SightCare Pills ... - Journal of the San Juan Islands - November 9th, 2023
- 6 Amazing Health Benefits Of Giloy (Tinospora cordifolia) - WION - November 9th, 2023
- The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising... - November 7th, 2023
Recent Comments